Biostable electrospun microfibrous scaffolds mitigate hypertrophic scar contraction in an immune-competent murine model.

Acta Biomater

Division of Plastic and Reconstructive Surgery, Department of Surgery, Duke University Medical Center, Box 3181, Durham, NC 27710, USA; Department of Pathology, Duke University Medical Center, Box 3712, Durham, NC 27710, USA. Electronic address:

Published: March 2016

Unlabelled: Burn injuries in the United States account for over one million hospital admissions per year, with treatment estimated at four billion dollars. Of severe burn patients, 30-90% will develop hypertrophic scars (HSc). In this study, we evaluate the impact of an elastomeric, randomly-oriented biostable polyurethane (PU) scaffold on HSc-related outcomes. In vitro, fibroblast-seeded PU scaffolds contracted significantly less and demonstrated fewer αSMA(+) myofibroblasts compared to fibroblast-seeded collagen lattices. In a murine HSc model, collagen coated PU (ccPU) scaffolds significantly reduced HSc contraction as compared to untreated control wounds and wounds treated with the clinical standard of care. Our data suggest that electrospun ccPU scaffolds meet the requirements to reduce HSc contraction including reduction of in vitro HSc related outcomes, diminished scar stiffness, and reduced scar contraction. While clinical dogma suggests treating severe burn patients with rapidly biodegrading skin equivalents, our data suggest that a more long-term scaffold may possess merit in reducing HSc.

Statement Of Significance: In severe burns treated with skin grafting, between 30% and 90% of patients develop hypertrophic scars (HSc). There are no therapies to prevent HSc, and treatments are marginally effective. This work is the first example we are aware of which studies the impact of a permanent electrospun elastomer on HSc contraction in a murine model that mimics the human condition. Collagen coated polyurethane scaffolds decrease αSMA+ myofibroblast formation in vitro, prevent stiffening of scar tissue, and mitigate HSc contraction. Unlike current standards of care, electrospun, polyurethane scaffolds do not lose architecture over time. We propose that the future bioengineering strategy of mitigating HSc contraction should consider a long-term elastomeric matrix which persists within the wound bed throughout the remodeling phase of repair.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.actbio.2015.12.025DOI Listing

Publication Analysis

Top Keywords

hsc contraction
20
hsc
10
scar contraction
8
murine model
8
severe burn
8
burn patients
8
develop hypertrophic
8
hypertrophic scars
8
scars hsc
8
collagen coated
8

Similar Publications

Introduction: Obstructive sleep apnoea (OSA) is characterised by blood oxygen desaturations and sleep disruptions manifesting undesirable consequences. Existing treatments including oral appliances, positive airway pressure (PAP) therapy and surgically altering the anatomy of the pharynx have drawbacks including poor long-term adherence or often involving irreversible, invasive procedures. Bilateral hypoglossal nerve stimulation (HNS) is a new treatment for managing OSA, and this study is intended to determine whether an HNS system is a safe and effective treatment option for adults with OSA.

View Article and Find Full Text PDF

Background: Effectiveness of disease-modifying treatment (DMT) in people affected by primary progressive multiple sclerosis (PPMS) is limited. Whether specific subgroups may benefit more from DMT in a real-world setting remains unclear. Our aim was to investigate the potential effect of DMT on disability worsening among patients with PPMS stratified by different disability trajectories.

View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to evaluate the effectiveness of short (<120 days) versus long (>180 days) antiviral prophylaxis for preventing cytomegalovirus (CMV) disease in pediatric liver transplant recipients by analyzing data from the Society of Pediatric Liver Transplantation registry between 2015 and 2019.
  • - Among the 199 enrolled participants, shorter prophylaxis resulted in higher occurrences of CMV DNAemia (26.8% vs. 13.8%) and CMV syndrome (18.8% vs. 6.9%) compared to longer prophylaxis, while end-organ disease rates were similar between the two groups.
  • - Long prophylaxis was associated with a significantly higher incidence of neutropenia (55
View Article and Find Full Text PDF

Microbial-derived Urolithin A Targets GLS1 to Inhibit Glutaminolysis and Attenuate Cirrhotic Portal Hypertension.

Cell Mol Gastroenterol Hepatol

September 2024

Laboratory of Interventional Radiology, Department of Minimally Invasive Interventional Radiology and Interventional Cancer Center, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China. Electronic address:

Background & Aims: Cirrhotic portal hypertension (CPH) is the leading cause of mortality in patients with cirrhosis. Over 50% of patients with CPH treated with current clinical pharmacotherapy still present variceal bleeding or sometimes death owing to insufficient reduction in portal pressure. Elevated intrahepatic vascular resistance (IHVR) plays a fundamental role in increasing portal pressure.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!